Adherex Technologies (NASDAQ:FENC – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Adherex Technologies to similar companies based on the strength of its dividends, valuation, analyst recommendations, institutional ownership, risk, earnings and profitability.
Profitability
This table compares Adherex Technologies and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adherex Technologies | 2.52% | 8.96% | 4.90% |
| Adherex Technologies Competitors | -2,391.72% | -204.89% | -14.89% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Adherex Technologies and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adherex Technologies | 0 | 1 | 4 | 1 | 3.00 |
| Adherex Technologies Competitors | 7859 | 13810 | 25855 | 1041 | 2.41 |
Adherex Technologies presently has a consensus price target of $17.50, indicating a potential upside of 30.11%. As a group, “Pharmaceuticals” companies have a potential upside of 29.95%. Given Adherex Technologies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Adherex Technologies is more favorable than its peers.
Volatility & Risk
Adherex Technologies has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Adherex Technologies’ peers have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.
Valuation & Earnings
This table compares Adherex Technologies and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Adherex Technologies | $66.37 million | -$9.74 million | 1,345.00 |
| Adherex Technologies Competitors | $3.56 billion | $3.18 billion | 556.81 |
Adherex Technologies’ peers have higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Adherex Technologies beats its peers on 10 of the 13 factors compared.
About Adherex Technologies
Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
